Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Brightgene Bio-medical Technology Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥23 Mil. Brightgene Bio-medical Technology Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-19 Mil.
Brightgene Bio-medical Technology Co's interest coverage for the quarter that ended in Mar. 2026 was 1.26.
The higher the ratio, the stronger the company's financial strength is.
SHSE:688166'
s Interest Coverage Range Over the Past 10 Years
Min: 1.75 Med: 19.73 Max: 558.5
Current: 2
SHSE:688166's Interest Coverage is ranked worse than 91.25% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs SHSE:688166: 2.00
Brightgene Bio-medical Technology Co (SHSE:688166) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Brightgene Bio-medical Technology Co Interest Coverage Related Terms
Brightgene Bio-medical Technology Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Brightgene Bio-medical Technology Co Interest Coverage Chart
SHSE:688166 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Brightgene Bio-medical Technology Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brightgene Bio-medical Technology Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brightgene Bio-medical Technology Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Brightgene Bio-medical Technology Co's Interest Coverage falls into.
Brightgene Bio-medical Technology Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brightgene Bio-medical Technology Co (SHSE:688166) has a Interest Coverage of 1.26 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Brightgene Bio-medical Technology Co and its competitors. This is 94% below median its historical median of 19.73. Over the past decade, Brightgene Bio-medical Technology Co's Interest Coverage has ranged from 1.75 to 558.50. According to the industry distribution chart, Brightgene Bio-medical Technology Co ranks #344 out of 377 companies in the Biotechnology industry, placing it in the top 91.2%.
Is Brightgene Bio-medical Technology Co's Interest Coverage too high?
Brightgene Bio-medical Technology Co's current Interest Coverage of 1.26 is 94% below median its 10-year median of 19.73. Over the past 10 years, this metric has ranged from a low of 1.75 to a high of 558.50. The Biotechnology industry median Interest Coverage is 106.07. Brightgene Bio-medical Technology Co's value of 1.26 is 98.8% below this industry median. Based on the distribution chart, Brightgene Bio-medical Technology Co ranks #344 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brightgene Bio-medical Technology Co ranks #344 out of 377 companies for Interest Coverage. This places Brightgene Bio-medical Technology Co in the lower half of its industry. The industry median Interest Coverage is 106.07. Brightgene Bio-medical Technology Co's value of 1.26 is 98.8% below this benchmark. Historically, Brightgene Bio-medical Technology Co's own Interest Coverage has ranged from 1.75 to 558.50 over the past decade. While the company's 10-year median is 19.73 vs. the industry median of 106.07, Brightgene Bio-medical Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brightgene Bio-medical Technology Co's current Interest Coverage of 1.26 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Brightgene Bio-medical Technology Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brightgene Bio-medical Technology Co's current Interest Coverage is 1.26, which is 94% below median its own 10-year median of 19.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.49, compared to a current price of ¥31.19 — trading 19% below its estimated fair value. The current Interest Coverage is 1.26, which is 94% below median its 10-year median of 19.73 and 98.8% below the Biotechnology industry median of 106.07. Brightgene Bio-medical Technology Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Interest Coverage is 1.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be undervalued.
The current stock price of ¥31.19 is trading 19% below its estimated GF Value™ of ¥38.49.
GuruFocus considers Brightgene Bio-medical Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688166:
Interest Coverage: 1.26 (94% below median its 10-year median of 19.73)
GF Value™: ¥38.49 vs. price of ¥31.19 (19% below fair value)
Industry Position: 98.8% below the Biotechnology median (#344 of 377)
No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brightgene Bio-medical Technology Co Business Description
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
84GF Score
Get the complete analysis for SHSE:688166
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688166 has been successfully added to your 
